| Symbol | ADPT |
|---|---|
| Name | ADAPTIVE BIOTECHNOLOGIES CORP |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 1165 EASTLAKE AVE E, SEATTLE, WA 98109 |
| Telephone | 206-659-0067 |
| Fax | — |
| — | |
| Website | https://www.adaptivebiotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001478320 |
| Description | Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. Additional info from NASDAQ: |
Director OWEN KATEY EINTERZ 🔴 sold 12.5K shares of Adaptive Biotechnologies Corp (ADPT) Transaction Date: Aug 31, 2026 | Filing ID: 000007
Read moreAdaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Read moreDirector OWEN KATEY EINTERZ 🔴 sold 9.6K shares of Adaptive Biotechnologies Corp (ADPT) at $26.00 Transaction Date: Aug 26, 2026 | Filing ID: 000005
Read more📋 Harlan Robins (Ex-Officer) plans to sell 402K shares of Adaptive Biotechnologies Corporation (at $25.44 each, total $10.2M) Filed: Aug 20, 2026 | ID: 000543
Read moreDirector HERSHBERG ROBERT 🟡 adjusted position in 30.7K shares (1 derivative) of Adaptive Biotechnologies Corp (ADPT) at $24.41 Transaction Date: Aug 18, 2026 | Filing ID: 000004
Read moreDirector NEUPERT PETER M 🟡 adjusted position in 124.7K shares (1 derivative) of Adaptive Biotechnologies Corp (ADPT) at $25.23 ($3.3M) Transaction Date: Aug 17, 2026 | Filing ID: 000003
Read more📋 Harlan Robins (Ex-Officer) plans to sell 216K shares of Adaptive Biotechnologies Corporation (at $25.49 each, total $5.5M) Filed: Aug 19, 2026 | ID: 000536
Read more📋 ROBERT M HERSHBERG (Director) plans to sell 31K shares of ADAPTIVE BIOTECHNOLOGIES CORPORATION (at $24.40 each, total $748K) Filed: Aug 18, 2026 | ID: 008364
Read more📋 Chad Robins (Officer) plans to sell 279K shares of Adaptive Biotechnologies Corporation (at $24.56 each, total $6.8M) Filed: Aug 18, 2026 | ID: 000527
Read more📋 Harlan Robins (Ex-Officer) plans to sell 261K shares of Adaptive Biotechnologies Corporation (at $24.56 each, total $6.4M) Filed: Aug 18, 2026 | ID: 000526
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06828991 | A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patient… | Phase2 | Diffuse Large B-Cell Lymphoma (DLBCL) | Recruiting | 2025-09-04 | 2030-04-01 | ClinicalTrials.gov |
| NCT06557330 | MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgki… | Phase2 | Lymphoma | Not_Yet_Recruiting | 2025-06-01 | 2028-03-30 | ClinicalTrials.gov |
| NCT05769829 | ImmuneSense™ IBD Study | — | Inflammatory Bowel Diseases | Terminated | 2022-10-31 | 2023-08-14 | ClinicalTrials.gov |
| NCT05255354 | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing… | — | Follicular Lymphoma | Recruiting | 2022-06-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05271630 | Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cel… | — | Multiple Myeloma | Active_Not_Recruiting | 2022-04-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT05112874 | ImmuneSense™ COVID-19 Cross-Reactivity Study | — | Coronavirus Disease | Withdrawn | 2021-12-15 | 2023-05-17 | ClinicalTrials.gov |
| NCT05054088 | ImmuneSense COVID-19 Variant Study | — | Covid19 | Completed | 2021-10-12 | 2022-07-28 | ClinicalTrials.gov |
| NCT04545333 | The clonoSEQ® Watch Registry | — | Acute Lymphoblastic Leukemia, Adult B-Cell | Terminated | 2020-10-13 | 2023-10-01 | ClinicalTrials.gov |
| NCT04583982 | ImmuneSense™ COVID-19 Study | — | Coronavirus Disease (COVID-19) | Completed | 2020-10-09 | 2020-12-04 | ClinicalTrials.gov |
| NCT04422314 | ImmuneSense Lyme Study | — | Lyme Disease | Completed | 2020-07-09 | 2021-10-30 | ClinicalTrials.gov |
| NCT04419519 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize E… | Phase2 | Chronic Lymphocytic Leukemia (CLL) | Active_Not_Recruiting | 2020-05-13 | 2027-05-01 | ClinicalTrials.gov |
| NCT04494893 | ImmuneRACE - Immune Response Action to COVID-19 Events | — | Covid19 | Completed | 2020-04-24 | 2021-04-23 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Venetoclax with anti CD20 monoclonal antibody | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Venetoclax monotherapy | Drug | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| clonoSEQ Assay | Other | Preclinical | Acute Lymphoblastic Leukemia, Adult B-Cell | TERMINATED | NCT04545333 |
| T-Detect™ SARS-CoV-2 Assay | Other | Preclinical | Coronavirus Disease (COVID-19) | COMPLETED | NCT04583982 |
| T-Detect Lyme | Other | Preclinical | Lyme Disease | COMPLETED | NCT04422314 |
| T-Detect COVID test | Other | Preclinical | Covid19 | COMPLETED | NCT05054088 |
| ClonoSEQ | Other | Preclinical | Follicular Lymphoma | RECRUITING | NCT05255354 |
| Rituximab | Other | Phase PHASE2 | Lymphoma | NOT_YET_RECRUITING | NCT06557330 |
| Bendamustine | Other | Phase PHASE2 | Lymphoma | NOT_YET_RECRUITING | NCT06557330 |
| ClonoSEQ | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma (DLBCL) | RECRUITING | NCT06828991 |
| Mosunetuzumab | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma (DLBCL) | RECRUITING | NCT06828991 |
| Venetoclax with anti CD20 monoclonal antibody | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Venetoclax monotherapy | Drug | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Proteasome Inhibitor | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| Immunomodulatory Agent | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| Autologous Stem Cell Transplant | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| T-Detect™ SARS-CoV-2 Assay | OTHER | Preclinical | Coronavirus Disease (COVID-19) | COMPLETED | NCT04583982 |
| T-Detect COVID test | DEVICE | Preclinical | Covid19 | COMPLETED | NCT05054088 |
| Rituximab | DRUG | Phase PHASE2 | Lymphoma | NOT_YET_RECRUITING | NCT06557330 |
| Bendamustine | DRUG | Phase PHASE2 | Lymphoma | NOT_YET_RECRUITING | NCT06557330 |
| ClonoSEQ | DEVICE | Preclinical | Follicular Lymphoma | RECRUITING | NCT05255354 |
| Mosunetuzumab | DRUG | Phase PHASE2 | Diffuse Large B-Cell Lymphoma (DLBCL) | RECRUITING | NCT06828991 |
| Venetoclax with anti CD20 monoclonal antibody | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Venetoclax monotherapy | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Proteasome Inhibitor | DRUG | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| Immunomodulatory Agent | DRUG | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| Autologous Stem Cell Transplant | OTHER | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |